FDA reveals COVID-19-related drug shortage

The US Food and Drug Administration (FDA) has revealed a COVID-19-related shortage of a drug, adding to concerns that the virus has the potential to massively disrupt medical supply chains.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

No coronavirus-related drug shortages yet, says EMA

11 March 2020 The European Medicines Agency has said that no drug shortages or supply disruptions due to the coronavirus outbreak have been reported, but that a steering group has convened to address the epidemic’s impact on the supply of medicines in the EU.

Big Pharma

China approves three Gilead remdesivir patents for COVID-19 treatment

27 February 2020 US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.

Big Pharma

Sanofi to create ‘world’s second biggest’ API manufacturer

27 February 2020 French drugmaker Sanofi is looking to create a new European manufacturer of active pharmaceutical ingredients, amid concerns over dependence on a Chinese manufacturing sector hit by coronavirus.